公开(公告)号：AU2015287696A1

公开(公告)日：2017-02-16

申请号：AU2015287696

申请日：2015-07-10

Applicant: ACADEMIA SINICA

Inventor： HSIEH PATRICK CH ,  WU PEI-JUNG ,  ROFFLER STEVE ,  CHENG BILL ,  LIANG CHI-MING

IPC: C07K2/00 ,  A61K38/00

Abstract: Disclosed herein is a multiple drugs delivery system and its uses in treating diseases. The multiple drugs delivery system includes, an anti-PEG antibody for directing the PEGylated therapeutic to the treatment site; and a hydrogel for retaining the anti-PEG antibody and/or the PEGylated therapeutic at the treatment site for at least 3 days. The hydrogel is selected from the group consisting of hyaluronan (HA) or a derivative of HA, collagen, gelatin, fibronectin, fibrinogen, alginate, chitosan, and a synthetic biocompatible polymer. The anti-PEG antibody and the hydrogel are present in the mixture in a ratio from about 1:1 (v/v) to 1:100 (v/v). At least two dosages of the PEGylated therapeutic, which may be the same or different, are administered to the subject, with each dosage being given at about 1 hour to about 1 week apart. Accordingly, a novel method of treating a subject having cancer or ischemia disease is also provided.

公开(公告)号：AU2015287696B2

公开(公告)日：2018-06-14

申请号：AU2015287696

申请日：2015-07-10

Applicant: ACADEMIA SINICA

Inventor： HSIEH PATRICK CH ,  WU PEI-JUNG ,  ROFFLER STEVE ,  CHENG BILL

IPC: C07K2/00 ,  A61K38/00

Abstract: Disclosed herein is a multiple drugs delivery system and its uses in treating diseases. The multiple drugs delivery system includes, an anti-PEG antibody for directing the PEGylated therapeutic to the treatment site; and a hydrogel for retaining the anti-PEG antibody and/or the PEGylated therapeutic at the treatment site for at least 3 days. The hydrogel is selected from the group consisting of hyaluronan (HA) or a derivative of HA, collagen, gelatin, fibronectin, fibrinogen, alginate, chitosan, and a synthetic biocompatible polymer. The anti-PEG antibody and the hydrogel are present in the mixture in a ratio from about 1:1 (v/v) to 1:100 (v/v). At least two dosages of the PEGylated therapeutic, which may be the same or different, are administered to the subject, with each dosage being given at about 1 hour to about 1 week apart. Accordingly, a novel method of treating a subject having cancer or ischemia disease is also provided.